Thyroid Carcinoma
Conditions
Interventions
None listed
Sponsors
Tottori University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Progressive thyroid carcinoma UICC stage >2 thyroid carcinoma including papillary, follicular, and indifferenciated thyroid carcinoma 2. Inprogressive thyroid carcinoma UICC stage 1 thyroid carcinoma including papillary and follicular thyroid carcinoma 3. Benign thyroid tumor Disgnosed as benign by ultrasound and fine needle aspiration cytology 4. Graves' disease Diagnosed by Guideline for the diagnosis of Graves' disease (JTA 2013) 5. Chronic thyroiditis Diagnosed by Guideline for the diagnosis of Chronic thyroiditis (JTA 2013) 6. Normal control Those who fulfill these 4 criteria 1) normal thyroid function 2) thyroid autoantibody (TgAb and/or TPOAb) negative 3) no thyroid nodule detected by ultrasound survey 4) no symptoms and signs were obtained and judged healthy by the researchers
Exclusion criteria
Exclusion criteria: 1. Advanced thyroid carcinoma 1) history of malignant tumor in other organs 2) pregnant or suspected of pregnancy 3) others not suitable for entry 2. Inadvanced thyroid carcinoma 1) history of malignant tumor in other organs 2) pregnant or suspected of pregnancy 3) others not suitable for entry 3. Benign thyroid tumor 1) history of malignant tumor in other organs 2) pregnant or suspected of pregnancy 3) others not suitable for entry 4. Graves' disease 1) history of malignant tumor in other organs 2) post thyroidectomy 3) post I-131 ablation 4) pregnant or suspected of pregnancy 5) others not suitable for entry 5. Chronic thyroiditis 1) history of malignant tumor in other organs 2) post thyroidectomy 3) pregnant or suspected of pregnancy 4) others not suitable for entry 6. Normal control 1) history of malignant tumor in other organs 2) pregnant or suspected of pregnancy 3) others not suitable for entry
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the titer of autoantibody against thyroid carcinoma in 6 groups (progressive thyroid carcinoma, nonprogressive thyroid carcinoma, benign thyroid nodule, Graves' disease, chronic thyroiditis, and normal control) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) To invastigate the change of titer in the treatment of thyroid carcinoma 2) To investigate the correlations between autoantibodies against thyroid carcinoma and clinical parameters including pathological diagnosis, cytological diagnosis, thyroid function test, thyroid autoantibodies, and imaging study 3) To investigate the safety including nonspecific antigen-antibody interaction | — |
Countries
Japan
Contacts
Public ContactShoichiro Izawa
Tottori University Hospital Division of Endocrinology and Metabolism
Outcome results
None listed